Enfortumab vedotin

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Enfortumab vedotin
Mar 14, 2025, 15:22 | Drugs
Enfortumab Vedotin (Padcev): What Patients Need To Know?
Enfortumab vedotin, also known as Padcev, is a groundbreaking antibody-drug conjugate (ADC) designed to treat…
Mar 2, 2025, 14:36 | Insight
Maite Bourlon: How to treat metastastic urothelial carcinoma after 1st line EV and Pembrolizumab
Maite Bourlon, Associate Professor and Head of the Urologic Oncology Clinic at the National Institute…
Feb 26, 2025, 10:54 | Oncolibrary
New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience
Title:  Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2…
Dec 27, 2024, 17:02 | Insight
Toni Choueiri: Top 10 GU Bladder/Kidney Cancer Trials for 2024
Toni Choueiri, Director of the Lank Center for GU Oncology at Dana-Farber Cancer Institute, shared…
Dec 4, 2024, 18:33 | Blog
Rasha Aboelhassan: By the end of the year, everyone is looking for achievements
Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital, posted on LinkedIn: "By the end…
Oct 14, 2024, 10:30 | Insight
MHRA Approves Merck and Astellas/Pfizer's Bladder Cancer Combination Therapy
The MHRA has approved the combination of Keytruda (pembrolizumab) and Padcev (enfortumab vedotin) as a…
Sep 9, 2024, 14:16 | Blog
Tom Powles: Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions
Tom Powles shared a post on X, about recent paper published in ESMO Open: The…
Aug 7, 2024, 11:11 | Drugs
Earle Burgess: Important information for those who use enfortumab vedotin in practice
Earle Burgess, Genitourinary Medical Oncologist at Atrium Health Levine Cancer, shared on LinkedIn: "Key question…
Jun 1, 2024, 23:26 | Blog
Vadim Koshkin: Our recent work highlighting a Grey Zone in metastatic urothelial carcinoma after enfortumab vedotin/pembrolizumab
Vadim Koshkin, Assistant Professor at University of California, San Francisco, shared a post on X/Twitter:…
May 31, 2024, 15:41 | Societies
Paolo Tarantino: More than 25 ASCO24 oral presentations by Dana-Farber Cancer Institute researchers
Paolo Tarantino shared a post by Dana-Farber Cancer Institute on X: "More than 25 ASCO24…
May 26, 2024, 13:42 | Insight
Some of the highlights while waiting for ASCO24 by Yakup Ergün
Yakup Ergün, Medical Oncologist at Ankara Numune Training and Research Hospital, shared a post on…
May 25, 2024, 08:14 | Insight
Niklas Klümper: ASCO abstracts on phase EV-202 results have just been released
Niklas Klümper, Resident in Urology and Researcher at the Institute for Experimental Oncology at the…
May 12, 2024, 00:24 | Insight
Karima Oualla: IBCG- AUA Bladder Cancer Forum
Karima Oualla, Professor of Medical Oncology at Hassan II University Hospital, shared a post on LinkedIn:…
Apr 30, 2024, 11:17 | Insight
New Paper Alert! Targeting NECTIN4. Predicting Response to Enfortumab Vedotin in Metastatic Urothelial Cancer
Targeting NECTIN4. Predicting Response to Enfortumab Vedotin in Metastatic Urothelial Cancer Authors: Niklas Klümper, MD,…
Apr 27, 2024, 14:44 | Insight
Aruni Ghose: Our review delves into the progress across urological malignancies and discusses future directions in ADC development
Aruni Ghose, Internal Medicine Resident at Barts Health NHS Trust, shared a post on LinkedIn:…
Apr 26, 2024, 17:55 | Insight
Piotr Wysocki: NECTIN4 amplification is a predictive factor for enfortumab vedotin efficacy
Piotr Wysocki recently shared on LinkedIn: "Kluemper et al. published results of a study evaluating NECTIN4…
Apr 12, 2024, 12:37 | Insight
Niklas Klümper: Happy to share our commentary about EV-302
Niklas Klümper, Resident in Urology and Researcher at the Institute for Experimental Oncology at the…
Mar 15, 2024, 15:26 | Insight
Enfortumab+pembrolizumab combination as the 1st line treatment of choice for advanced urothelial cancer - summary by Piotr J. Wysocki
Piotr J. Wysocki, Professor of Medicine, Head of Department of Oncology at Jagiellonian University Hospital,…
Feb 1, 2024, 17:24 | Drugs
Day 2 of GU24 ASCO Highlights by Oncology Brothers
Oncology Brothers shared on their X/Twitter: "Day 2 of GU24 ASCO Highlights 1. UNITE: EV…
Feb 1, 2024, 15:42 | Opinion
Thomas Powles: Enfortumab Vedotin and Pembrolizumab shows broad spectrum of activity for Regional Recurrence, Progression-free survival and Overall Survival in all subgroups
Feb 1, 2024, 15:19 | Opinion
Paolo Tarantino: Nectin4 amplification predicts response to enfortumab vedotin in metastatic urothelial carcinoma
Paolo Tarantino, Medical Oncologist and Research Fellow at the Dana-Farber Cancer Institute, shared by Niklas…
Jan 31, 2024, 17:49 | Insight
Earle Burgess: Initial results from a small pilot study in late mCRPC where there are limited to no effective treatment options available
Earle Burgess, Genitourinary Oncologist at Atrium Health Levine Cancer, shared on LinkedIn: "Enfortumab vedotin is…
Jan 18, 2024, 15:12 | Blog
Maria Natalia Gandur Quiroga: Immuno-Oncology Advances in Genitourinary Cancers
Maria Natalia Gandur Quiroga shared a post on LinkedIn: "Immuno-Oncology Advances in Genitourinary Cancers: Introduction:…
Oct 26, 2023, 16:27 | Blog
Benjamin Auberger: This major study naturally raises several questions
Quoting Benjamin Auberger, Oncologist at CHRU Brest, on LinkedIn: "A wow presidential session with a…
Oct 23, 2023, 15:26 | Insight
Tom Powles: Enfortumab vedotin and Pembrolizumab improving PFS and OS by 55% and 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%)
Tom Powles, Director of Barts Cancer Centre, shared on Twitter: "Enfortumab vedotin and Pembrolizumab improving…
All: 25 Posts: 1 - 100
Special Coverage